Real-world pattern of inflammatory bowel disease (IBD), raised faecal calprotectin and IBD red flags in patients with moderate-to-severe psoriasis: interim results from the EPIC study

被引：0
|
作者：
Warren, Richard B. [1 ]
Ghosh, Subrata [2 ]
Carter, Ben [3 ]
Bartlett, Sean [4 ]
Powles, Emma [4 ]
Millward, Rachael [4 ]
Watcham, Shelley [4 ]
Blanthorn-Hazell, Sophee [4 ]
Crooks, James [4 ]
Hansell, Chris [4 ]
Millar, Julie [5 ]
Williams, Claire [5 ]
Migas, Sylwia [5 ]
Hajne, Joanna [5 ]
Hayee, Bu [6 ]
机构：
[1] Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester, Lancs, England
[2] Cork Univ Hosp, Cork, Ireland
[3] Kings Coll London, Inst Psychiat, London, England
[4] AbbVie Ltd, Maidenhead, Berks, England
[5] Northwest EHlth Ltd, Manchester, Lancs, England
[6] Kings Coll Hosp NHS Fdn Trust, London, England
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2022年 / 187卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P23
引用
收藏
页码：42 / 42
页数：1
相关论文
共 50 条
  • [21] REAL-WORLD EFFECTIVENESS AND SAFETY IN A PHASE 4 STUDY OF TILDRAKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
    Bhatia, N.
    Vasquez, J. G.
    Schenkel, B.
    Rozzo, S. J.
    Heim, J.
    VALUE IN HEALTH, 2023, 26 (06) : S57 - S57
  • [22] Patients' quality of life in a Phase 4 real-world study of tildrakizumab in moderate-to-severe plaque psoriasis
    Heim, Jayme
    Vasquez, J. Gabriel
    Rozzo, Stephen J.
    Schenkel, Brad
    Bhatia, Neal
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB204 - AB204
  • [23] Clinical efficacy and durability of subcutaneous infliximab in patients with moderate-to-severe inflammatory bowel disease : a real-world data from a Korean multicentre prospective cohort study
    Kim, K.
    Hong, S. N. H.
    Kang, S. B. K.
    Lee, K. M.
    Koo, J. S. K.
    Jung, Y.
    Lee, B. J. L.
    Yoon, H. Y.
    Kim, H. W.
    Lim, Y. J.
    Lee, H. S.
    Lee, Y. J.
    Lee, J.
    Lee, C. K.
    Moon, J. M.
    Shin, S. Y.
    Seo, J.
    Choi, C. H.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1410 - I1412
  • [24] Initial report on the Month 12 results from the Psoriasis Study of Health Outcomes (PSoHO) for patients with moderate-to-severe psoriasis treated with biologics in the real-world setting
    Costanzo, Antonio
    Paul, Carle
    Carrascosa, Jose Manuel
    Tada, Yayoi
    Brnabic, Alan
    Schuster, Christopher
    Reed, Catherine
    Abrahamy, Michael
    Riedl, Elisabeth
    Pinter, Andreas
    Mahar, Patrick
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 26 - 26
  • [25] QUALITY OF LIFE AND TREATMENT SATISFACTION WITH TILDRAKIZUMAB IN MODERATE-TO-SEVERE PSORIASIS PATIENTS: 52-WEEK INTERIM DATA OF THE REAL-WORLD POSITIVE STUDY
    Augustin, Matthias
    Sommer, Raquel
    Reguiai, Ziad
    Gerdes, Sascha
    Dauden, Esteban
    Weger, Wolfgang
    Maul, Julia-Tatjana
    Laws, Philip
    Naldi, Luigi
    Ghislain, Pierre-Dominique
    de Jong, Elke
    Mburu, Sicily
    Koscielny, Volker
    Massana, Eric
    Kasujee, Ismail
    Mrowietz, Ulrich
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [26] Characteristics and treatment pattern comparisons of a real-world cohort of patients eligible and ineligible for moderate-to-severe psoriasis clinical trials
    Wu, J.
    Araujo, A.
    Nordstrom, B.
    Goldblum, O.
    Solotkin, K.
    Lin, C. -Y.
    Johnston, J.
    Kistler, K.
    Fraeman, K.
    Malatestinic, W.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 84 - 84
  • [27] REAL-WORLD TRENDS IN CLINICAL CHARACTERISTICS OF INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS INITIATING VEDOLIZUMAB OVER TIME IN ISRAEL
    Weil, C.
    Chodick, G.
    Shalev, V
    Demuth, D.
    Petrakis, I
    Ben Baruch, O.
    Tsukinovsky, S.
    Yarden, A.
    VALUE IN HEALTH, 2018, 21 : S142 - S142
  • [28] Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study
    Augustin, M.
    Sator, P. G.
    von Kiedrowski, R.
    Conrad, C.
    Rigopoulos, D.
    Romanelli, M.
    Ghislain, P-D
    Torres, T.
    Ioannides, D.
    Aassi, M.
    Schulz, B.
    Jagiello, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (10) : 1796 - 1804
  • [29] Switching Vedolizumab from IV to SC Injection in Inflammatory Bowel Disease Patients with Active Disease: Real-World Experience from a German IBD Cohort
    Kubesch, Alica
    Kruse, Nina
    Jungheim, Florian
    Balaban, Uemniye
    Stratmann, Katharina
    Sprinzl, Kathrin
    Dienethal, Antje
    Krause, Thomas
    Zeuzem, Stefan
    Blumenstein, Irina
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (24)
  • [30] Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian Network for inflammatory bowel diseases (SN-IBD):-Preliminary results
    Viola, A.
    Fiocco, G.
    Alibrandi, A.
    Macaluso, F. S.
    Cappello, M.
    Privitera, A. C.
    Magri, G.
    Garufi, S.
    Centritto, A.
    Ventimiglia, M.
    Giuffrida, E.
    Ferracane, C.
    Costantino, G.
    Renna, S.
    Orlando, A.
    Fries, W.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S578 - S578
12345